Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Rating of “Buy” by Analysts

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been assigned an average rating of “Buy” from the nine research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $65.1429.

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 23rd. Zacks Research raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, June 17th. Citigroup boosted their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Finally, Canaccord Genuity Group increased their price objective on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th.

Kiniksa Pharmaceuticals International Stock Up 4.6%

Shares of NASDAQ:KNSA opened at $63.95 on Friday. The stock has a market cap of $4.92 billion, a PE ratio of 71.06 and a beta of 0.07. The company’s fifty day moving average is $56.42 and its 200 day moving average is $49.21. Kiniksa Pharmaceuticals International has a 52 week low of $26.27 and a 52 week high of $67.53.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. During the same period in the prior year, the business posted $0.11 earnings per share. The company’s revenue was up 55.5% on a year-over-year basis. Sell-side analysts anticipate that Kiniksa Pharmaceuticals International will post 1.25 EPS for the current year.

Insider Buying and Selling

In related news, insider John F. Paolini sold 58,424 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the completion of the sale, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. This represents a 47.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of the stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the sale, the chief executive officer directly owned 431,904 shares of the company’s stock, valued at $22,398,541.44. The trade was a 52.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 628,427 shares of company stock valued at $32,833,228 over the last three months. 51.98% of the stock is owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Large investors have recently modified their holdings of the business. KBC Group NV bought a new position in Kiniksa Pharmaceuticals International during the 1st quarter valued at approximately $34,000. Smartleaf Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $36,000. EverSource Wealth Advisors LLC grew its position in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter valued at approximately $41,000. Finally, CIBC Private Wealth Group LLC purchased a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter valued at approximately $41,000. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.